Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of JS111 capsules in EGFR-mutant advanced non-small cell lung cancer
CTR20250661Phase 2Active
- Sponsor
- Junjing Bio
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of js111 in non-small cell lung cancer (NSCLC), sponsored by Junjing Bio. Started Apr 2025; status: active.
02
Drugs
js111
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250661.